BIOLASE, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Detail)

Stockholders' Equity - Additional Information (Detail)										3 Months Ended		9 Months Ended
Stockholders' Equity - Additional Information (Detail)	Sep. 27, 2018 USD ($) $ / shares	Sep. 21, 2018 $ / shares shares	Sep. 10, 2018 $ / shares shares	Jun. 15, 2018 BoardMember $ / shares shares	May 14, 2018 $ / shares shares	May 10, 2018 shares	May 09, 2018 shares	Jan. 26, 2018 $ / shares shares	Jan. 25, 2018 $ / shares shares	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) $ / shares shares	Mar. 06, 2018 USD ($) $ / shares	Dec. 31, 2017 shares
Stockholders Equity [Line Items]
Reverse stock split ratio						0.2
Description of reverse stock split												At BIOLASE’s annual meeting of stockholders on May 9, 2018 (the “Annual Meeting”), BIOLASE stockholders approved an amendment to BIOLASE’s Restated Certificate of Incorporation, as amended, to effect a reverse stock split of BIOLASE common stock, at a ratio ranging from one-for-five (1:5) to one-for-fifteen (1:15), with the final ratio to be determined by the BIOLASE board of directors (the “Board”). Immediately after the Annual Meeting, the Board approved a one-for-five (1:5) reverse stock split of the outstanding shares of BIOLASE common stock (the “Reverse Stock Split”). On May 10, 2018, the Company filed an amendment (the “Amendment”) to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, effective as of 11:59 p.m. on May 10, 2018. The Amendment also reduced the authorized shares of common stock from 200,000,000 shares to 40,000,000 shares.
Common stock, shares authorized						40,000,000	200,000,000			40,000,000		40,000,000			40,000,000
Compensation expense related to stock options \| $										$ 600,000	$ 500,000	$ 1,900,000	$ 1,600,000
Net impact of stock-based compensation expense to earnings per basic share \| $ / shares										$ (0.03)	$ (0.03)	$ (0.09)	$ (0.11)
Net impact of stock-based compensation expense to earnings per diluted share \| $ / shares										$ (0.03)	$ (0.03)	$ (0.09)	$ (0.11)
Total unrecognized compensation expense \| $										$ 4,000,000		$ 4,000,000
Unrecognized share based compensation expense to be recognized over weighted-average period												2 years 1 month 6 days
Reversal of share based compensation expense \| $												$ 100,000	$ 700,000
Number of new board members. \| BoardMember				2
Outstanding stock options, RSUs and warrants excluded from diluted loss per share										5,800,000	5,400,000	5,800,000	5,400,000
Original Western Alliance Warrant
Stockholders Equity [Line Items]
Initial exercise price of warrants \| $ / shares														$ 2.35
Western Alliance Warrant
Stockholders Equity [Line Items]
Initial exercise price of warrants \| $ / shares	$ 2.13
Warrants expire date	Sep. 27, 2028
Stock Options \| Employees
Stockholders Equity [Line Items]
Stock options granted									360,000
Awards valued per share \| $ / shares									$ 2.11
Options expiration period									10 years
Options vesting description												The options vest ratably over the 36-month period, commencing on February 25, 2018.
Share-based Compensation Arrangement by Share-based Payment Award, Monthly Ratable Award Vesting Period									36 months
Share Based Compensation Arrangement By Share Based Payment Award, Vesting Commencement Date									Feb. 25, 2018
Restricted Stock Units (RSUs)
Stockholders Equity [Line Items]
Granted												2,747,000
Restricted Stock Units (RSUs) \| Employees
Stockholders Equity [Line Items]
Awards valued per share \| $ / shares					$ 1.45
Options vesting description												These awards were valued at $1.45 per share, the closing price of BIOLASE common stock on the grant date, and were fully vested on the grant date
Granted					10,127
Restricted Stock Units (RSUs) \| Board Members
Stockholders Equity [Line Items]
Awards valued per share \| $ / shares					$ 1.45
Options vesting description												398,275 shares to certain Board members of the Company. These awards were valued at $1.45 per share, the closing price of BIOLASE common stock on the grant date, and fully vest on the first anniversary of the grant date
Granted					398,275
Restricted Stock Units (RSUs) \| New Board Members
Stockholders Equity [Line Items]
Awards valued per share \| $ / shares				$ 1.25
Options vesting description												These awards were valued at $1.25 per share, the closing price of BIOLASE common stock on the grant date, and vest fully on May 9, 2019.
Granted				155,000
Award vesting date				May 09, 2019
2002 Stock Incentive Plan
Stockholders Equity [Line Items]
Common stock authorized for issuance										3,100,000		3,100,000
Common stock issued pursuant to options exercised												1,000,000
Options and restricted stock units outstanding										1,800,000		1,800,000
2002 Stock Incentive Plan \| Restricted Stock Units (RSUs) \| President And Chief Executive Officer
Stockholders Equity [Line Items]
Awards valued per share \| $ / shares								$ 2.00
Granted								40,000
2018 Long-Term Incentive Plan
Stockholders Equity [Line Items]
Common stock authorized for issuance		3,300,000
Options and restricted stock units outstanding										2,400,000		2,400,000
Options available for future grants										900,000		900,000
2018 Long-Term Incentive Plan \| Vest on September 10, 2019
Stockholders Equity [Line Items]
Vesting percentage		50.00%
2018 Long-Term Incentive Plan \| Vest on September 10, 2020
Stockholders Equity [Line Items]
Vesting percentage		50.00%
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Employees
Stockholders Equity [Line Items]
Awards valued per share \| $ / shares		$ 2.06
Options vesting description												(i) 50% of 24,271 shares vest on September 10, 2019 and the remaining 50% vest on September 10, 2020; and (ii) 6,117 shares fully vest on March 15, 2019, subject to continued service through the applicable vesting dates.
Granted		30,388
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Employees \| Vest on September 10, 2019
Stockholders Equity [Line Items]
Granted		24,271
Award vesting date		Sep. 10, 2019
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Employees \| Vest on September 10, 2020
Stockholders Equity [Line Items]
Award vesting date		Sep. 10, 2020
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Employees \| Vest on March 15, 2019
Stockholders Equity [Line Items]
Granted		6,117
Award vesting date		Mar. 15, 2019
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Chief Executive Officer
Stockholders Equity [Line Items]
Awards valued per share \| $ / shares			$ 2.17
Options vesting description												(i) 54% of the total grant is subject to time vesting with 33% vesting on August 7, 2019 and the remaining 67% vesting ratably semi-annually over the two-year period commencing on February 7, 2020; and (ii) 46% of the awards is subject to specific 2019, 2020 and 2021 performance criteria, with vesting upon satisfaction of the applicable performance criteria, subject to continued service through the applicable vesting dates.
Share-based Compensation Arrangement by Share-based Payment Award, Monthly Ratable Award Vesting Period			2 years
Share Based Compensation Arrangement By Share Based Payment Award, Vesting Commencement Date			Feb. 07, 2020
Granted			650,000
Award vesting date			Aug. 07, 2019
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Chief Executive Officer \| Vest Percentage
Stockholders Equity [Line Items]
Vesting percentage			54.00%
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Chief Executive Officer \| Vest on August 7, 2019
Stockholders Equity [Line Items]
Vesting percentage			33.00%
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Chief Executive Officer \| Vesting Commence on February 7, 2020
Stockholders Equity [Line Items]
Vesting percentage			67.00%
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Chief Executive Officer \| Vesting Awards Subject To Specific 2019, 2020 and 2021 Performance Criteria
Stockholders Equity [Line Items]
Vesting percentage			46.00%
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Board Members, Employees and Consultants
Stockholders Equity [Line Items]
Awards valued per share \| $ / shares					$ 1.45
Options vesting description												These awards were valued at $1.45 per share, the closing price of BIOLASE common stock on the grant date, and vest 40% on December 31, 2018 and 60% on December 31, 2019, subject to continued service through the applicable vesting dates.
Granted					1,193,850
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Board Members, Employees and Consultants \| Vest on December 31, 2018
Stockholders Equity [Line Items]
Vesting percentage					40.00%
Award vesting date					Dec. 31, 2018
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Board Members, Employees and Consultants \| Vest on December 31, 2019
Stockholders Equity [Line Items]
Vesting percentage					60.00%
Award vesting date					Dec. 31, 2019
Minimum [Member]
Stockholders Equity [Line Items]
Reverse stock split ratio							0.2
Maximum
Stockholders Equity [Line Items]
Reverse stock split ratio							0.067
Maximum \| Original Western Alliance Warrant
Stockholders Equity [Line Items]
Warrants issued to purchase shares of common stock equal value \| $														$ 120,000
Maximum \| Western Alliance Warrant
Stockholders Equity [Line Items]
Warrants issued to purchase shares of common stock equal value \| $	$ 120,000